

# GATA3 (L50-823) Mouse Monoclonal Antibody

*For In Vitro Diagnostic Use (IVD)*

## Product Identification

| REF     | Description                    |
|---------|--------------------------------|
| 390M-14 | 0.1 mL concentrate             |
| 390M-15 | 0.5 mL concentrate             |
| 390M-16 | 1.0 mL concentrate             |
| 390M-17 | 1.0 mL predilute ready-to-use  |
| 390M-18 | 7.0 mL predilute ready-to-use  |
| 390M-10 | 25.0 mL predilute ready-to-use |

## Symbol Definitions

| KEY-CODE | keycode                    |
|----------|----------------------------|
| P        | predilute                  |
| C        | concentrate                |
| A        | ascites                    |
| E        | serum                      |
| S        | supernatant                |
| DIL      | concentrate dilution range |

## Intended Use

This antibody is intended for *in vitro* diagnostic (IVD) use.

GATA3 (L50-823) Mouse Monoclonal Primary Antibody is intended for laboratory use in the detection of the GATA3 protein in formalin-fixed, paraffin-embedded human tissue stained in qualitative immunohistochemistry (IHC) testing.

The results using this product should be interpreted by a qualified pathologist in conjunction with the patient's relevant clinical history, other diagnostic tests and proper controls.

## Summary and Explanation

GATA binding protein 3 or GATA3, is a zinc finger transcription factor and plays an important role in promoting and directing cell proliferation, development, and differentiation in many tissues and cell types.<sup>1-4</sup> The human GATA3 gene has been mapped to chromosome 10p15.<sup>3</sup> GATA3 expression is primarily seen in breast carcinoma and urothelial carcinoma.<sup>1-2</sup> Anti-GATA3 can also be useful in the identification of unknown primary carcinoma when carcinomas of the breast or bladder are a possibility.

## Principles and Procedures

The stated primary antibody may be used as the primary antibody for immunohistochemical staining of formalin-fixed, paraffin-embedded tissue sections. In general, immunohistochemical staining in conjunction with a HRP or Alk Phos linked detection system allows the visualization of antigens via the sequential application of a specific antibody (primary antibody) to the antigen, a secondary antibody (link antibody) to the primary antibody, an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and a coverslip applied. Results are interpreted using a light microscope.

## Materials and Methods

### Reagents Provided

| Product Composition                |                                                             |
|------------------------------------|-------------------------------------------------------------|
| Predilute: diluted in              | Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide |
| Concentrate: diluted in            | Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide |
| Host                               | Mouse                                                       |
| Isotype                            | IgG <sub>1</sub> /k                                         |
| Recommended working dilution range | 1:100-1:500                                                 |
| Source                             | Supernatant                                                 |

See product label for lot specific information for the following:

1. Antibody immunoglobulin concentration
2. Source details

### Reconstitution, Mixing, Dilution, Titration

Prediluted antibody is ready-to-use and optimized for staining. No reconstitution, mixing, dilution, or titration is required. The concentrated antibody is optimized to be diluted to within the dilution range using Cell Marque Diamond Diluent.

### Materials and Reagents Needed But Not Provided

The following reagents and materials may be required for staining but are not provided with the primary antibody:

1. Positive and negative control tissue
2. Microscope slides, positively charged
3. Drying oven capable of maintaining a temperature of 53-65°C
4. Staining jars or baths

5. Timer
6. Xylene or xylene substitute
7. Ethanol or reagent alcohol  
*Note: Cell Marque's one-step pretreatment, Trilogy™ (cat. #920P-06), can replace both 6 and 7 above.*
8. Deionized or distilled water
9. Heating equipment, such as an electric pressure cooker, for tissue pretreatment step
10. Detection system, such as HiDef Detection™ HRP Polymer System (cat. #954D-20) or HiDef Detection™ Alk Phos Polymer System (cat. #962D-20)
11. Chromogen, such as DAB Substrate Kit (cat. #957D-20) or Permanent Red Chromogen Kit (cat. #960D-10)
12. TBS IHC Wash Buffer + Tween® 20 (cat. #935B-09)
13. Hematoxylin or other counterstain
14. Antibody diluents, such as Diamond: Antibody Diluent (cat. #938B-05) or Emerald: Antibody Diluent (cat. #936B-08)
15. Peroxide Block (cat. #925B-05) for use with HRP
16. Avidin-Biotin Blocking Reagents for use with streptavidin-biotin detection
17. Negative Control Reagent (cat. #939B-02 for universal)
18. Mounting Medium
19. Cover glass
20. Light microscope (40–400x)

### Storage and Handling

Store at 2–8°C. Do not freeze.

To ensure proper reagent delivery and stability of the antibody after every run, the cap must be replaced and the bottle must be immediately placed in the refrigerator in an upright position.

Every antibody reagent is expiration dated. When properly stored, the reagent is stable to the date indicated on the label. Do not use reagent beyond the expiration date for the prescribed storage method.

There are no definitive signs to indicate instability of this product; therefore, positive and negative controls should be run simultaneously with unknown specimens. Contact Cell Marque technical support if there is a suspected indication of reagent instability.

### Specimen Collection and Preparation for Analysis

Routinely processed, neutral-buffered formalin-fixed, paraffin-embedded, tissues are suitable for use with this primary antibody when used with Cell Marque detection kits (see Materials, Reagents, and Equipment Needed But Not Provided section). Note: Cell Marque evaluates performance only on human tissues. The recommended tissue fixative is 10% neutral-buffered formalin. Variable results may occur as a result of prolonged fixation or special processes such as decalcification of bone marrow preparations.

Each section should be cut to the appropriate thickness (approximately 3 µm) and placed on a positively charged glass slide. Slides containing the tissue section may be baked for at least 2 hours (but not longer than 24 hours) in a 53–65°C oven.

### Warnings and Precautions

1. Take reasonable precautions when handling reagents. Use disposable gloves and lab coats when handling suspected carcinogens or toxic materials (example: xylene).
2. Avoid contact of reagents with eyes and mucous membranes. If reagents come in contact with sensitive areas, wash with copious amounts of water.
3. Patient specimens and all materials contacting them should be handled as biohazardous materials and disposed of with proper precautions. Never pipette by mouth.
4. Avoid microbial contamination of reagents, as this could produce incorrect results.
5. The user must validate incubation times and temperatures.
6. The prediluted, ready-to-use reagents are optimally diluted, and further dilution may result in loss of antigen staining.
7. The concentrated reagents may be diluted optimally based on validation by user. Any diluent used that is not specifically recommended herein must likewise be validated by the user for both its compatibility and effect on stability.
8. When used according to instructions, this product is not classified as a hazardous substance. The preservative in the reagent is less than 0.1% sodium azide and does not meet the OSHA (USA) criteria for hazardous substance at the stated concentration. See SDS.
9. The user must validate any storage conditions other than those specified in the package insert.
10. Diluent may contain bovine serum albumin and supernatant may contain bovine serum. The products containing fetal bovine serum and products containing bovine serum albumin are purchased from commercial suppliers. Certificates of Origin for the animal source used in these products are on file at Cell Marque. The certificates support that the bovine sources are from countries with negligible BSE risk and state sources of bovine from USA and Canada.
11. As with any product derived from biological sources, proper handling procedures should be used.

### Instructions For Use

Recommended Staining Protocols for the stated primary antibody:

#### HiDef HRP:

HiDef Detection™ HRP Polymer System (cat. #954D-20)

1. Epitope Retrieval Technique: HIER in a Pressure Cooker. Pressure Cooker Temperature (°C): 110. Pressure Cooker Time (Minutes): 15. Epitope Retrieval Reagent: Trilogy
2. Rinse with DI Water
3. Rinse with TBST Buffer
4. Peroxide Block Incubation Time (Minutes): 10
5. Rinse with DI Water
6. Rinse with TBST Buffer
7. Antibody Incubation Time (Minutes): 10–30
8. Rinse with DI Water
9. Wash with TBST Buffer (Minutes): 5
10. HiDef HRP Detection Amplifier Incubation Time (Minutes): 10

11. Rinse with DI Water
12. Wash with TBST Buffer (Minutes): 5
13. HiDef HRP Detection Polymer Detector Incubation Time (Minutes): 10
14. Rinse with DI Water
15. Wash with TBST Buffer (Minutes): 5
16. Rinse with DI Water
17. DAB Incubation Time (Minutes): 1-10
18. Rinse with DI Water
19. Counterstain with hematoxylin
20. Rinse with DI Water
21. Dehydrate and Coverslip

#### HiDef Alk Phos:

HiDef Detection™ Alk Phos Polymer System (cat. #962D-20)

1. Epitope Retrieval Technique: HIER in a Pressure Cooker. Pressure Cooker Temperature (°C): 110. Pressure Cooker Time (Minutes): 15. Epitope Retrieval Reagent: Trilog
2. Rinse with DI Water
3. Rinse with TBST Buffer
4. Antibody Incubation Time (Minutes): 10-30
5. Rinse with DI Water
6. Wash with TBST Buffer (Minutes): 5
7. HiDef AP Detection Amplifier Incubation Time (Minutes): 10
8. Rinse with DI Water
9. Wash with TBST Buffer (Minutes): 5
10. HiDef AP Detection Polymer Detector Incubation Time (Minutes): 10
11. Rinse with DI Water
12. Wash with TBST Buffer (Minutes): 5
13. Rinse with DI Water
14. Perm Red Incubation Time (Minutes): 15-30
15. Rinse with DI Water
16. Counterstain with hematoxylin
17. Rinse with DI Water
18. Dehydrate and Coverslip

## Quality Control Procedures

### Positive Tissue Control

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. Control tissues should be fresh autopsy, biopsy or surgical specimens prepared or fixed as soon as possible in a manner identical to the test sections. Use of a tissue section fixed or processed differently from the test specimen will serve to provide control for all reagents and method steps except fixation and tissue processing.

A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation. Positive tissue control for the stated primary antibody may include the following:

| Positive Tissue Control |               |
|-------------------------|---------------|
| Tissue                  | Visualization |
| Breast carcinoma        | Nuclear       |
| Urothelial carcinoma    | Nuclear       |

Known positive tissue controls should be utilized only for monitoring the correct performance of processed tissues and test reagents, not as an aid in determining a specific diagnosis of patient samples. If the positive tissue controls fail to demonstrate appropriate positive staining, results with the test specimens must be considered invalid.

### Negative Tissue Control

The same tissue used for the positive tissue control may be used as the negative tissue control. The variety of cell types present in most tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

### Unexplained Discrepancies

Unexplained discrepancies in controls should be referred to Cell Marque technical support immediately. If quality control results do not meet specifications, patient results are invalid. See the Troubleshooting section of this insert. Identify and correct the problem, then repeat the entire procedure with the patient samples.

### Negative Control Reagent

A negative control reagent must be run for every specimen to aid in the interpretation of results. A negative control reagent is used in place of the primary antibody to evaluate nonspecific staining. The slide should be treated with negative control reagent, matching the host species of the primary antibody, and ideally having the same IgG concentration. The incubation period for the negative control reagent should equal the primary antibody incubation period.

## Interpretation of Results

The immunostaining procedure causes a colored reaction product to precipitate at the antigen sites localized by the primary antibody. Refer to the appropriate detection system package insert for expected color reactions. A qualified pathologist experienced in immunohistochemistry procedures must evaluate positive and negative tissue controls before interpreting results.

### Positive Tissue Control

The stained positive tissue control should be examined first to ascertain that all reagents are functioning properly. The presence of an appropriately colored reaction product within the target cells is indicative of positive reactivity. Refer to the package insert of the detection system used for expected color reactions. Depending on the incubation length and potency of the hematoxylin used, counterstaining will result in a pale to dark blue coloration of cell nuclei. Excessive or incomplete counterstaining may compromise proper interpretation of

results. If the positive tissue control fails to demonstrate appropriate positive staining, any results with the test specimens are considered invalid.

### Negative Tissue Control

The negative tissue control should be examined after the positive tissue control to verify the specific labeling of the target antigen by the primary antibody. The absence of specific staining in the negative tissue control confirms the lack of antibody cross reactivity to cells or cellular components. If specific staining occurs in the negative tissue control, results with the patient specimen are considered invalid. Nonspecific staining, if present, will have a diffuse appearance. Sporadic light staining of connective tissue may also be observed in sections from tissues that are not optimally fixed. Intact cells should be used for interpretation of staining results. Necrotic or degenerated cells show non-specific staining.

### Patient Tissue

Patient specimens should be examined last. Positive staining intensity should be assessed within the context of any background staining of the negative reagent control. As with any immunohistochemical test, a negative result means that the antigen in question was not detected, not that the antigen is absent in the cells or tissue assayed. A panel of antibodies may aid in the identification of false negative reactions (see Summary of Expected Results section). The morphology of each tissue sample should also be examined utilizing a hematoxylin and eosin stained section when interpreting any immunohistochemical result. The patient's morphologic findings and pertinent clinical data must be interpreted by a qualified pathologist.

### Limitations

1. Color does not affect performance.
2. This reagent is "for professional use only" as immunohistochemistry is a multiple step process that requires specialized training in the selection of the appropriate reagents, tissues, fixation, processing; preparation of the immunohistochemistry slide; and interpretation of the staining results.
3. For laboratory use only.
4. For *in vitro* diagnostic use.
5. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning, or contamination with other tissues or fluids may produce artifacts, antibody trapping, or false negative results. Inconsistent results may result from variations in fixation and embedding methods, as well as from inherent irregularities within the tissue.
6. Excessive or incomplete counterstaining may compromise proper interpretation of results.
7. The clinical interpretation of any positive staining, or its absence, must be evaluated within the context of clinical history, morphology, other histopathological criteria as well as other diagnostic tests. This antibody is intended to be used in a panel of antibodies if applicable. It is the responsibility of a qualified pathologist to be familiar with the antibodies, reagents, diagnostic panels, and methods used to produce the stained preparation. Staining must be performed in a certified, licensed laboratory under the supervision of a pathologist who is responsible for reviewing the stained slides and assuring the adequacy of positive and negative controls.
8. Cell Marque provides antibodies and reagents at optimal dilution for use as instructed. Any deviation from recommended test procedures may invalidate expected results. Appropriate controls must be employed and documented. Users in any circumstance must accept responsibility for interpretation of patient results.

9. Cell Marque provides primary antibodies in concentrated format so that the user may subsequently optimally dilute for use subject to the user's determination of and adherence to suitable validation techniques. Users must validate the use of any diluents other than what is recommended herein. Once the primary is validated to be suitable for use, any deviation from recommended test procedures may invalidate expected results. Appropriate controls must be employed and documented. Users in any circumstance must accept responsibility for interpretation of patient results.
10. This product is not intended for use in flow cytometry.
11. Reagents may demonstrate unexpected reactions in previously untested tissues. The possibility of unexpected reactions even in tested tissue groups cannot be completely eliminated because of biological variability of antigen expression in neoplasms, or other pathological tissues. Contact Cell Marque technical support with any suspected, documented unexpected reactions.
12. Tissues from persons infected with hepatitis B virus and containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.
13. When used in blocking steps, normal sera from the same animal source as the secondary antisera may cause false negative or false positive results because of the effect of autoantibodies or natural antibodies.
14. False positive results may be seen because of non immunological binding of proteins or substrate reaction products. They may also be caused by pseudoperoxidase activity (erythrocytes), endogenous peroxidase activity (cytochrome C), or endogenous biotin (example: liver, brain, breast, kidney) subject to the type of immunostaining technique used.
15. As with any immunohistochemistry test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells or tissue assayed.
16. The prediluted antibody products are optimized as a ready-to-use product. Because of the possibility of variation in tissue fixation and processing, it may be necessary to increase or decrease the primary antibody incubation time on individual specimens.
17. The antibody, in combination with detection systems and accessories, detects antigen(s) that survive routine formalin fixation, tissue processing and sectioning. Users who deviate from recommended test procedures remain, as they would in any circumstance, responsible for interpretation and validation of patient results.

### Summary of Expected Results

See the following tables of reactivity:

| Normal Study     |               |         |                     |
|------------------|---------------|---------|---------------------|
| Tissue           | # Stained (+) | Total # | Notes               |
| Brain Cerebrum   | 0             | 3       |                     |
| Brain Cerebellum | 0             | 3       |                     |
| Adrenal Gland    | 2             | 7       | Medulla weak, focal |
| Ovary            | 0             | 6       |                     |
| Pancreas         | 0             | 8       |                     |
| Parathyroid      | 7             | 8       |                     |

| Normal Study          |               |         |                                                                                          |
|-----------------------|---------------|---------|------------------------------------------------------------------------------------------|
| Tissue                | # Stained (+) | Total # | Notes                                                                                    |
| Pituitary             | 1             | 3       | Adenohypophysis weak, rare                                                               |
| Testis                | 0             | 8       |                                                                                          |
| Thyroid               | 0             | 5       |                                                                                          |
| Breast                | 8             | 8       | Ducts +; lobules +                                                                       |
| Spleen                | 5             | 9       | Red pulp weak in scattered cells                                                         |
| Tonsil                | 8             | 8       | Interfollicular cells weak                                                               |
| Thymus                | 8             | 8       | Cortical +; medullary lymphocytes +                                                      |
| Bone Marrow           | 2             | 8       | Lymphocytes +                                                                            |
| Lung                  | 0             | 3       |                                                                                          |
| Heart                 | 0             | 8       |                                                                                          |
| Esophagus             | 0             | 6       |                                                                                          |
| Stomach               | 0             | 7       |                                                                                          |
| Small Intestine       | 0             | 6       |                                                                                          |
| Colon                 | 0             | 7       |                                                                                          |
| Liver                 | 0             | 7       |                                                                                          |
| Salivary Gland        | 4             | 5       | 4/4 Acini focal, weak                                                                    |
| Gall Bladder          | 0             | 5       |                                                                                          |
| Kidney                | 6             | 6       | Distal tubules +; collecting ducts +                                                     |
| Bladder               | 7             | 7       | Urothelium +                                                                             |
| Prostate              | 6             | 8       | Basal cells focal, weak                                                                  |
| Uterus                | 0             | 5       |                                                                                          |
| Fallopian Tube        | 0             | 8       |                                                                                          |
| Ureter                | 5             | 5       | Urothelium +                                                                             |
| Cervix                | 3             | 9       | 3/5 Squamous epithelium weak, focal                                                      |
| Skeletal Muscle       | 0             | 7       |                                                                                          |
| Smooth Muscle         | 0             | 3       |                                                                                          |
| Skin                  | 6             | 7       | Epidermis weak/moderate; 3/3 sebaceous glands moderate; 1/2 hair follicles weak/moderate |
| Peripheral Nerve      | 0             | 6       |                                                                                          |
| Mesothelium           | 0             | 3       |                                                                                          |
| Placenta              | 8             | 8       | Trophoblasts +                                                                           |
| Para-adrenal ganglion | 1             | 1       | Ganglion cells weak/moderate                                                             |

| Disease Tissue Study                    |               |         |                                    |
|-----------------------------------------|---------------|---------|------------------------------------|
| Tissue                                  | # Stained (+) | Total # | Notes                              |
| Invasive ductal carcinoma               | 119           | 132     |                                    |
| Urothelial carcinoma                    | 69            | 80      |                                    |
| Breast ductal carcinoma in-situ         | 35            | 35      |                                    |
| Skin squamous cell carcinoma            | 29            | 36      |                                    |
| Basal cell carcinoma                    | 12            | 12      |                                    |
| Mesothelioma                            | 9             | 16      |                                    |
| Synovial sarcoma                        | 8             | 11      |                                    |
| Lung squamous cell carcinoma            | 6             | 29      |                                    |
| Breast invasive lobular carcinoma       | 5             | 5       |                                    |
| Metastatic breast carcinoma             | 5             | 7       |                                    |
| Sebaceous adenoma                       | 4             | 4       |                                    |
| Cervix squamous cell carcinoma          | 3             | 3       |                                    |
| Bladder squamous cell carcinoma         | 2             | 2       |                                    |
| Fibrosarcoma                            | 2             | 5       |                                    |
| Schwannoma                              | 2             | 9       |                                    |
| Adult T-cell lymphoma/leukemia          | 1             | 1       |                                    |
| Angioimmunoblastic T-cell lymphoma      | 1             | 1       |                                    |
| Carcinoid tumor                         | 1             | 1       | Ovarian                            |
| Cervical intraepithelial neoplasia II   | 1             | 1       |                                    |
| Ewings sarcoma                          | 1             | 18      |                                    |
| Leiomyosarcoma                          | 1             | 4       |                                    |
| Lung adenocarcinoma                     | 1             | 36      | Rare cells +                       |
| Malignant peripheral nerve sheath tumor | 1             | 2       |                                    |
| Metastatic urothelial carcinoma         | 1             | 1       |                                    |
| Ovarian Brenner tumor                   | 1             | 1       |                                    |
| Renal cell carcinoma                    | 1             | 9       | Chromophobe renal cell carcinoma + |

| Disease Tissue Study                   |               |         |       |
|----------------------------------------|---------------|---------|-------|
| Tissue                                 | # Stained (+) | Total # | Notes |
| Salivary gland squamous cell carcinoma | 1             | 1       |       |
| Sebaceous carcinoma                    | 1             | 2       |       |
| Undifferentiated soft tissue sarcoma   | 1             | 1       |       |
| Astrocytoma                            | 0             | 4       |       |
| Choriocarcinoma                        | 0             | 1       |       |
| Clear cell ovarian carcinoma           | 0             | 2       |       |
| Colorectal carcinoma                   | 0             | 123     |       |
| Dermatofibrosarcoma protuberans        | 0             | 2       |       |
| Esophagus squamous cell carcinoma      | 0             | 23      |       |
| Follicular dendritic cell sarcoma      | 0             | 1       |       |
| Follicular lymphoma                    | 0             | 3       |       |
| Follicular thyroid carcinoma           | 0             | 2       |       |
| Ganglioneuroblastoma                   | 0             | 1       |       |
| Glioblastoma                           | 0             | 2       |       |
| Hepatocellular carcinoma               | 0             | 11      |       |
| Kaposi's Sarcoma                       | 0             | 19      |       |
| Leiomyoma                              | 0             | 1       |       |
| Liposarcoma                            | 0             | 6       |       |
| Lung adenosquamous carcinoma           | 0             | 6       |       |
| Mantle cell lymphoma                   | 0             | 3       |       |
| Medullary thyroid carcinoma            | 0             | 18      |       |
| Merkel cell carcinoma                  | 0             | 1       |       |
| Metastatic colorectal carcinoma        | 0             | 1       |       |
| Metastatic ovarian carcinoma           | 0             | 1       |       |
| Myxoid liposarcoma                     | 0             | 1       |       |
| Neurofibroma                           | 0             | 25      |       |
| Oral squamous cell carcinoma           | 0             | 1       |       |
| Ovarian endometrioid carcinoma         | 0             | 1       |       |
| Ovarian mucinous carcinoma             | 0             | 2       |       |

| Disease Tissue Study                         |               |         |            |
|----------------------------------------------|---------------|---------|------------|
| Tissue                                       | # Stained (+) | Total # | Notes      |
| Ovarian mucinous cystadenoma                 | 0             | 1       |            |
| Ovarian serous carcinoma                     | 0             | 9       | High grade |
| Ovarian serous cystadenoma                   | 0             | 1       |            |
| Pancreatic ductal adenocarcinoma             | 0             | 10      |            |
| Papillary thyroid carcinoma                  | 0             | 20      |            |
| Perivascular epithelioid cell tumor (PEComa) | 0             | 1       |            |
| Prostate carcinoma                           | 0             | 9       |            |
| Rhabdomyosarcoma                             | 0             | 11      |            |
| Stomach carcinoma diffuse type               | 0             | 20      |            |
| Stomach carcinoma intestinal type            | 0             | 28      |            |
| Uterus stromal sarcoma                       | 0             | 1       |            |

## Troubleshooting

1. If the positive control exhibits weaker staining than expected, other positive controls run during the same staining run should be checked to determine if it is because of the primary antibody or one of the common secondary reagents.
2. If the positive control is negative, other positive controls used on the same run should be checked to determine if the underlying cause relates to the primary antibody or one of the common secondary reagents. Tissues may have been improperly collected, fixed or deparaffinized. The proper procedure should be followed for collection, storage, and fixation.
3. If excessive background staining occurs, high levels of endogenous biotin may be present. A biotin blocking step should be included unless a biotin-free detection system is being used in which case any biotin present would not be a contributing factor to background staining.
4. If all of the paraffin has not been removed, the deparaffinization procedure should be repeated.
5. If tissue sections wash off the slide, slides should be checked to ensure that they are positively charged. Other possibilities that could have adverse affect on tissue adhesion include insufficient drying of the tissue section on the slide prior to staining or fixation in formalin that was not properly neutral-buffered. Tissue thickness may also be a contributing factor.

For corrective action, refer to the Instructions for Use section or contact Cell Marque technical support at [techsupport@cellmarque.com](mailto:techsupport@cellmarque.com).

## References

1. Higgins JP, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. *Am J Surg Pathol.* 2007; 31:673-80.
2. Liu, H, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. *Am J Clin Pathol.* 2012; 138:57-64.
3. Joulin V, et al. A T-cell specific TCR delta DNA binding protein is a member of the human GATA family. *EMBO J.* 1991; 10: 1809-16.
4. Labastie M, et al. Structure and expression of the human GATA3 gene. *Genomics*; 21:1-6.

## Disclaimers

\*TWEEN is a registered trademark of Croda International PLC.

©2023 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH is a trademark of Sigma-Aldrich Co. LLC, registered in the US and other countries. Cell Marque, Trilogy, Declere, and HiDef Detection are trademarks of Sigma-Aldrich Co. LLC or its affiliates.




[www.cellmarque.com](http://www.cellmarque.com)



Cell Marque Corporation

6600 Sierra College Blvd. • Rocklin, CA 95677 USA • 916-746-8900



EMERGO EUROPE B.V.

Westervoortsedijk 60, 6827 AT Arnhem, The Netherlands



CM Template #2.4v2

Implementation date 28 Sep 2023